August 2025
1. UPRIMNY C, von Guggenberg E, Sviridenko A, Bayerschmidt S, et al
   Diagnostic Performance of the (68)Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors.
   J Nucl Med. 2025 Aug 28:jnumed.125.269863. doi: 10.2967/jnumed.125.269863.
   

   >> Share

   
   July 2025
2. BANG YH, Kim JH, Kim YH, Kim HR, et al
   Distinct Prognostic Roles of (18)F-FDG PET Metabolic Response Assessed After Induction Chemotherapy or Chemoradiotherapy in Localized Esophageal Squamous Cell Carcinoma.
   J Nucl Med. 2025 Jul 3:jnumed.125.269775. doi: 10.2967/jnumed.125.269775.
   

   >> Share

   
   June 2025
3. VON HINTEN J, Viering O, Bundschuh RA, Cagliyan F, et al
   Feasibility of Short-Term Redifferentiation in Patients with Radioactive Iodine-Refractory Metastatic Thyroid Cancer.
   J Nucl Med. 2025 Jun 5:jnumed.125.270055. doi: 10.2967/jnumed.125.270055.
   

   >> Share

   
   April 2025
4. SHI B, Zhang Y, Wu S, Xu D, et al
   CD70-Targeted [(18)F]RCCB6 Immuno-PET/CT Imaging in Patients with Nasopharyngeal Carcinoma: A Proof-of-Concept Study.
   J Nucl Med. 2025 Apr 30:jnumed.125.269585. doi: 10.2967/jnumed.125.269585.
   

   >> Share

   
   
5. DERLIN T, Kleine-Dopke D, Neubert L, Ross TL, et al
   Initial Experience with Dual-Time-Point [(18)F]Flurpiridaz PET/CT for Localization of Parathyroid Adenomas in Primary Hyperparathyroidism.
   J Nucl Med. 2025 Apr 24:jnumed.124.269387. doi: 10.2967/jnumed.124.269387.
   

   >> Share

   
   March 2025
6. HAUSMANN P, Zschaeck S, Furth C, Nikulin P, et al
   Tumor Asphericity in FDG PET Is an Independent Prognostic Parameter Improving Risk Stratification in Patients with Head and Neck Squamous Cell Carcinoma.
   J Nucl Med. 2025 Mar 13:jnumed.124.268972. doi: 10.2967/jnumed.124.268972.
   

   >> Share

   
   February 2025
7. DU H, Hao X, Lin B, Tang M, et al
   (177)Lu-Labeled Anticlaudin 6 Monoclonal Antibody for Targeted Therapy in Esophageal Cancer.
   J Nucl Med. 2025 Feb 6:jnumed.124.268487. doi: 10.2967/jnumed.124.268487.
   

   >> Share

   
   January 2025
8. VON GUGGENBERG E, di Santo G, Uprimny C, Bayerschmidt S, et al
   Safety, Biodistribution, and Radiation Dosimetry of the (68)Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors.
   J Nucl Med. 2025 Jan 16:jnumed.124.268877. doi: 10.2967/jnumed.124.268877.
   

   >> Share

   
   September 2024
9. DONG Y, Wang Z, Hu X, Sun Y, et al
   [(18)F]AlF-NOTA-FAPI-04 PET/CT for Predicting Pathologic Response of Resectable Esophageal Squamous Cell Carcinoma to Neoadjuvant Camrelizumab and Chemotherapy: A Phase II Clinical Trial.
   J Nucl Med. 2024 Sep 26:jnumed.124.268557. doi: 10.2967/jnumed.124.268557.
   

   >> Share

   
   
10. AL-IBRAHEEM A, Abdlkadir A, Herrmann K, Bomanji J, et al
    Diagnostic Accuracy of [(18)F]FDG PET/MRI in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Metaanalysis.
    J Nucl Med. 2024 Sep 12:jnumed.124.268049. doi: 10.2967/jnumed.124.268049.
    

    >> Share

    
    
11. WRAY R, Mauguen A, Michaud L, Leithner D, et al
    Development of (18)F-Fluoromisonidazole Hypoxia PET/CT Diagnostic Interpretation Criteria and Validation of Interreader Reliability, Reproducibility, and Performance.
    J Nucl Med. 2024 Sep 12:jnumed.124.267775. doi: 10.2967/jnumed.124.267775.
    

    >> Share

    
    July 2024
12. CLEMENT C, Leclere JC, Maheo C, Le Pennec R, et al
    Diagnostic Performance of (18)F-FDG PET/CT According to Delay After Treatment to Detect Subclinical Recurrence of Head and Neck Squamous Cell Carcinoma.
    J Nucl Med. 2024 Jul 11:jnumed.124.267391. doi: 10.2967/jnumed.124.267391.
    

    >> Share

    
    
13. AL-NAQEEB G, Munger E, Ramanathan AL, Makarewicz A, et al
    Paraplegic Patient with Metastatic Papillary Thyroid Cancer: A Multidisciplinary Approach to Radioactive Iodine Therapy Safety and Efficacy Strategy.
    J Nucl Med. 2024 Jul 11:jnumed.123.266955. doi: 10.2967/jnumed.123.266955.
    

    >> Share

    
    April 2024
14. GREENSPAN BS, Hofman MS, Buscombe J
    The Accomplishments and Legacy of Saul Hertz, MD.
    J Nucl Med. 2024;65:659-663.
    

    >> Share

    
    March 2024
15. HAIDER SP, Zeevi T, Sharaf K, Gross M, et al
    Impact of (18)F-FDG PET Intensity Normalization on Radiomic Features of Oropharyngeal Squamous Cell Carcinomas and Machine Learning-Generated Biomarkers.
    J Nucl Med. 2024 Mar 21:jnumed.123.266637. doi: 10.2967/jnumed.123.266637.
    

    >> Share

    
    
16. CYTRYN SL, Pandit-Taskar N, Lumish MA, Maron SB, et al
    (18)F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer.
    J Nucl Med. 2024 Mar 21:jnumed.123.267186. doi: 10.2967/jnumed.123.267186.
    

    >> Share

    
    
17. GREENSPAN BS, Hofman MS, Buscombe J
    Commentary on "Radioactive Iodine: A Living History".
    J Nucl Med. 2024;65:495.
    

    >> Share

    
    February 2024
18. LEUNG KH, Rowe SP, Sadaghiani MS, Leal JP, et al
    Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT.
    J Nucl Med. 2024 Feb 29:jnumed.123.267048. doi: 10.2967/jnumed.123.267048.
    

    >> Share

    
    
19. KOVACS DG, Ladefoged CN, Andersen KF, Brittain JM, et al
    Clinical Evaluation of Deep Learning for Tumor Delineation on (18)F-FDG PET/CT of Head and Neck Cancer.
    J Nucl Med. 2024 Feb 22:jnumed.123.266574. doi: 10.2967/jnumed.123.266574.
    

    >> Share

    
    January 2024
20. GU B, Yang Z, Du X, Xu X, et al
    Imaging of Tumor Stroma Using (68)Ga-FAPI PET/CT to Improve Diagnostic Accuracy of Primary Tumors in Head and Neck Cancer of Unknown Primary: A Comparative Imaging Trial.
    J Nucl Med. 2024 Jan 25:jnumed.123.266556. doi: 10.2967/jnumed.123.266556.
    

    >> Share

    
    
21. ZHAO L, Pang Y, Fang J, Chen J, et al
    Design, Preclinical Evaluation, and Clinical Translation of (68)Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma.
    J Nucl Med. 2024 Jan 4:jnumed.123.266183. doi: 10.2967/jnumed.123.266183.
    

    >> Share

    
    December 2023
22. VENTURA D, Dittmann M, Buther F, Schafers M, et al
    Diagnostic Performance of [(18)F]TFB PET/CT Compared with Therapeutic Activity [(131)I]Iodine SPECT/CT and [(18)F]FDG PET/CT in Recurrent Differentiated Thyroid Carcinoma.
    J Nucl Med. 2023 Dec 21:jnumed.123.266513. doi: 10.2967/jnumed.123.266513.
    

    >> Share

    
    November 2023
23. GUNTHER T, Holzleitner N, Viering O, Beck R, et al
    Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [(68)Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer.
    J Nucl Med. 2023 Nov 9:jnumed.123.266537. doi: 10.2967/jnumed.123.266537.
    

    >> Share

    
    
24. VIERING O, Gunther T, Holzleitner N, Dierks A, et al
    CCK(2) Receptor-Targeted PET/CT in Medullary Thyroid Cancer Using [(68)Ga]Ga-DOTA-CCK-66.
    J Nucl Med. 2023 Nov 2:jnumed.123.266380. doi: 10.2967/jnumed.123.266380.
    

    >> Share

    
    October 2023
25. LASCHINSKY C, Theurer S, Herold T, Rawitzer J, et al
    Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in Patients with Papillary Thyroid Carcinoma.
    J Nucl Med. 2023 Oct 26:jnumed.123.266044. doi: 10.2967/jnumed.123.266044.
    

    >> Share

    
    May 2023
26. MALIHA PG, Mendelsohn AH, Czernin J, Howard T, et al
    Obstructive Sialadenitis from Oral Squamous Cell Carcinoma: [(68)Ga]Ga-FAPI-46 PET-Positive and [(18)F]FDG PET-Negative.
    J Nucl Med. 2023 May 25:265498. doi: 10.2967/jnumed.123.265498.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share